Search

Tutorial on thalassemia focused on best treatment

Almost 90 delegates from Shiraz and other cities in Iran learned how to identify the best treatment for each thalassemia patient at the EHA-SHRC Hematology Tutorial on Thalassemia on May 10-11, 2018 in Shiraz, Iran.

Read more

All-encompassing meeting on ALL highly rated by participants

Almost 200 delegates from over 30 countries benefitted from stimulating and excellent discussions about Acute Lymphoblastic Leukemia (ALL) at the EHA-SWG Scientific Meeting on New Molecular Insights and Innovative Management Approaches for Acute Lymphoblastic Leukemia on April 12-14, 2018 in…

Read more

EHA-Balkan Hematology Day 2024

EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 5th edition of the EHA-Balkan Hematology Day.

Read more

EU Parliament agrees on pharmaceutical legislation stance

On April 10, the European Parliament adopted its position on the revision of the EU pharmaceutical legislation.

Read more

Mentoring peer-peer networks – a recipe for success

Isabel Peset1 & Alba Maiques-Diaz2

1 Senior Scientist, Microscopy, Medicines Discovery Catapult, Manchester, UK;
2 Postdoctoral scientist, Biomedical Epigenomics group, IDIBAPS, Barcelona, Spain; YoungEHA committee member.

Read more

EHA-AAH Balkan Mini Hematology Tutorial 2021

EHA is joining forces with the Albanian Association of Hematology (AAH) to organize the EHA-AAH Balkan Hematology Mini Tutorial.

Read more

EHA-SWG Scientific Meeting on Aging and Hematology

Dates: October 12-14, 2018
Location: Warsaw, Poland
Chair: D Bron

Organized by:
EHA & the EHA Scientific Working Group on Aging and Hematology

Organizing committee:

D Bron, Institut Jules Bordet, Brussels, Belgium
L Adès, Hopital Saint Louis, Paris, France
R Cordoba, Fundacion Jimenez Diaz University Hospital, Madrid, Spain
T Fulöp, Université…

Read more

A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.

Read more